22 September 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) informs that its krill harvesting vessels now return to shore for scheduled upgrades and maintenance.
Offshore production volumes in 2022 improved considerably compared to previous years. Total volumes in the first nine months of 2022 were 50,100 MT, which is 23% above the 40,650 MT produced in the same period last year.
“We are pleased with our krill harvesting operations this year. Our crew has done a great job of significantly increasing production whilst operating our vessels in a safe and sustainable manner. After two challenging seasons, this year’s krill harvesting is on track to meet our expectation to annually produce 55,000-60,000 MT”, CEO Matts Johansen commented.
The support vessel Antarctic Provider left Antarctica in early September, carrying Qrill Aqua for customers in Europe. The company expects to restart the krill harvesting in Antarctica during the second half of November 2022.
For further information, please contact
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.